anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count \>2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is \> or \< than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
A Hospital Error-Limiting Program (HELP) directed primarily at reduction of hospital errors in the delivery of medications, goods, services or procedures in patient treatment without a requirement to create patient labels and with the ability to verify frequency of dosage and other treatment specifications. The invention includes a patient wrist identification band with preprinted barcode. The barcode should be selected to correspond with the standard used to barcode unit dose medications. The portable computer should be small in size and equipped with a communication link with the host computer or barcode reader. The portable computer should preferably be coupled directly to the host computer means of the hospital for data transmission by a communication link. The portable computer should be loaded with physician's orders for medications, goods, services or procedures for specific patients. Before medications, goods, services or procedures are administered to a patient, hospital personnel will scan the machine readable code on the patient's identification band, and then the machine readable code on the unit dose(s) of the medications, goods, services, or procedures will be scanned. The portable computer will compare these readings with the doctor's orders and other internal files as required and verify that the administration of the identified medications, goods, services or procedures is either correct or not correct.
Dementia is a syndrome of impairments of cortical functions caused by brain diseases. More than 55 million people worldwide are currently living with dementia, with nearly 10 million new cases each year. Alzheimer's disease (AD) is the most common form of dementia and may account for 60-70% of patients with dementia. Mild cognitive impairment (MCI) is an intermediate state between normal cognitive aging and dementia. About 10% to 15% of patients with MCI progress to dementia each year. In recent years, studies have found that there is an earlier stage before MCI, that is, the stage of subjective cognitive impairment (SCI). SCI is a stage between normal aging and MCI, which is manifested by the self-reported experience of worsening or more frequent memory loss but not supported by objective evidence. Subjects with SCI are more likely to develop AD. According to the US CDC data, the prevalence of SCI among adults aged 65 years and older is 11.7%. Therefore, it is crucial to find intervention strategies to prevent the progression of SCI to MCI and dementia. However, drug interventions are currently ineffective in the prevention and treatment of such diseases. Based on the synaptic plasticity, more and more studies focus on non-drug interventions. Our research group previously found non-drug interventions (cognitive training, exercise therapy) can effectively delay cognitive decline in the elderly. Therefore, this project plans to conduct a multi-site, randomized, parallel-controlled clinical trial to examine the effect of 3 years-Tai Chi exercise intervention on cognitive function in SCI subjects and to provide a new clinical basis for the prevention and treatment of cognitive disorders.
Glucose control is fundamental in the treatment of type 2 diabetes (DM2). Studies suggest that drugs that boost levels of glucagon-like peptide (GLP-1) improve glycemic control and have long-term beneficial effect on the function of pancreatic beta cells. Objective: To compare the short and long term effects of sitagliptin (which inhibits the DPP-IV enzyme, increasing the levels of GLP-1) with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide. Effects on beta cell function and on metabolic profile were analyzed. Methods: 40 patients with DM2, HbA1c between 6.6 to 10%, in use of metformin and glibenclamide will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group). Measurements of HbA1c, metabolic and hormonal profile at fasting and post-meal (every 30 minutes for 4 hours) will be evaluated before and after 6 months (short term) and 12 months (long term) of adding sitagliptin or NPH insulin.
Cytokines are small secreted proteins that have specific effects on cellular interactions and are crucial for functioning of the immune system. Cytokines are involved in almost all diseases, but as microscopic chemical compounds they cannot be visualized at imaging for obvious reasons. Several imaging manifestations have been well recognized owing to the development of cytokine therapies such as those with bevacizumab (antibody against vascular endothelial growth factor) and chimeric antigen receptor (CAR) T cells and the establishment of new disease concepts such as interferonopathy and cytokine release syndrome. For example, immune effector cell-associated neurotoxicity is the second most common form of toxicity after CAR T-cell therapy toxicity, and imaging is recommended to evaluate the severity. The emergence of COVID-19, which causes a cytokine storm, has profoundly impacted neuroimaging. The central nervous system is one of the systems that is most susceptible to cytokine storms, which are induced by the positive feedback of inflammatory cytokines. Cytokine storms cause several neurologic complications, including acute infarction, acute leukoencephalopathy, and catastrophic hemorrhage, leading to devastating neurologic outcomes. Imaging can be used to detect these abnormalities and describe their severity, and it may help distinguish mimics such as metabolic encephalopathy and cerebrovascular disease. Familiarity with the neuroimaging abnormalities caused by cytokine storms is beneficial for diagnosing such diseases and subsequently planning and initiating early treatment strategies. The authors outline the neuroimaging features of cytokine-related diseases, focusing on cytokine storms, neuroinflammatory and neurodegenerative diseases, cytokine-related tumors, and cytokine-related therapies, and describe an approach to diagnosing cytokine-related disease processes and their differentials. ©RSNA, 2024 Supplemental material is available for this article.
The invention relates to a hydrophobic medicine candesartan cilexetil nanoemulsion and a preparation method thereof. The candesartan cilexetil nanoemulsion with the grain size of 10 to 130 nm comprises 1 weight part of candesartan cilexetil, 1 to 30 weight parts of oil, 2 to 105 weight parts of surfactant and 30 to 200 weight parts of water. The candesartan cilexetil nanoemulsion is prepared by an emulsion-solvent volatilization method. The method is practical and simple and high in repeatability. The candesartan cilexetil nanoemulsion improves the solubility of slightly soluble medicine such as candesartan cilexetil, enhances the adhesivity of the medicine to small intestine wall and improves intestinal absorption ability. Compared with candesartan cilexetil mixed suspension, the candesartan cilexetil nanoemulsion has the advantages that: the bioavailability in rats is improved by 3 to 10 times; and the curative effect of the candesartan cilexetil medicine can be exerted completely.
This study aims to evaluate the impact of a multimodal cognitive intervention, the Cognitive Enrichment Program (CEP), on episodic memory, executive functions, psychological well-being and daily life activities in traumatic brain injured (TBI) older adults, as compared to an active control group that receives only usual care in the form of holistic rehabilitation. The experimental design is a semi-randomized, controlled, before-after study with blinded outcome measurement. French-speaking participants aged 55 years or older and having sustained a mild, moderate or severe TBI at least 6 months before enrollment, were recruited by clinical coordinators from one hospital and from two outpatient interdisciplinary rehabilitation centres. The CEP consists of three intervention modules, Introduction and self-awareness, Attention and Memory, and Executive functions, which were conducted with groups of 5 participants, in 90-minute sessions, twice weekly, during 12 weeks. The CEP was conducted by an experienced clinical neuropsychologist. Assessments of intervention effects were performed by trained evaluators, who were blinded to group assignment of participants, in two separate sessions lasting about 90 minutes each. There were three assessment time-points: baseline (pre-intervention - T0); 14-weeks (post-intervention - T1); 6-months post-intervention (follow-up - T2). Primary outcome measures (neuropsychological and self-report) were chosen to measure targeted effects of the CEP and generalization measures (self-report) were used to evaluate broader effects of the intervention. Control measures were also used to control for spontaneous recovery.
Checkpoint inhibitor-induced pneumonitis (CIP) is characterized clinically by dyspnea, cough and tachypnea. Hypoxia results from a lymphocyte-dominated alveolitis leading to ground glass opacities and consolidations observed by CT scan. Histological findings include lymphocytic infiltrates, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Moreover, CIP in most cases leads to discontinuation of checkpoint inhibitory therapy and steroids limit the therapeutic effect of checkpoint inhibitors resulting in progression of the underlying malignant disease. Therefore, there is a need of other therapeutic options in CIP that ideally could abrogate the alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effect on the immune system. The focus of the present invention is to deliver a solution to that problem by the topic application of VIP (vasoactive intestinal peptide, a peptide of 28 amino acids). A drug for inhalative VIP therapy is commercially available under the name Aviptadil.
The invention provides application of combined use of cisplatin and RNF31 inhibitor in preparation of a medicament for treating liver cancer. The invention also provides application of the RNF31 gene detection in preparation of a kit for detecting prognosis of a liver cancer patient. The invention also provides application of the RNF31 gene as a target spot in screening drugs for treating liver cancer. The invention also provides application of the RNF31 inhibitor in preparing a medicament for treating liver cancer. The invention defines the influence of RNF31 on DNA homologous recombination repair, inhibits RNF31 to reduce the activity of RAD51 and reduces the homologous recombination repair capability, and shows that RNF31 influences the drug resistance of tumor cells by regulating and controlling homologous recombination repair; the invention combines the liver cancer cell line, the cisplatin and the RNF31 inhibitor, has better killing effect on tumor cells, and verifies that the RNF31 inhibitor is a potential drug for treating liver cancer. The invention confirms that RNF31 is highly expressed in liver cancer tissues, is obviously related to prognosis of liver cancer patients, and is a potential liver cancer diagnosis index.
A system including a database, a healthcare provider interface and a respondent interface for assisting in the selection, administration and scoring of measurement tools to be provided to respondents. The database includes a plurality of diagnostic domains, respondent infomation for respondents, and measurement tool, data objects. The measurement tool data objects identify measurement tools and include conditional operators to select a subset of the measurement tools. The health care provider interface is configured to accept a selection of a diagnostic domain. The respondent interface includes measurement tool selection logic and scoring logic. The database is configured to provide a measurement tool data object based on the selected domain and a respondent type. The system evaluates the measurement tool data object using additional respondent information to select at least one measurement tool. The respondent interface administers the selected measurement tools to respondents and to scores completed measurement tools.
Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
ABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided.
We previously described an approach called RealSeqS to evaluate aneuploidy in plasma cell-free DNA through the amplification of ~350,000 repeated elements with a single primer. We hypothesized that an unbiased evaluation of the large amount of sequencing data obtained with RealSeqS might reveal other differences between plasma samples from patients with and without cancer. This hypothesis was tested through the development of a machine learning approach called Alu Profile Learning Using Sequencing (A-PLUS) and its application to 7615 samples from 5178 individuals, 2073 with solid cancer and the remainder without cancer. Samples from patients with cancer and controls were prespecified into four cohorts used for model training, analyte integration, and threshold determination, validation, and reproducibility. A-PLUS alone provided a sensitivity of 40.5% across 11 different cancer types in the validation cohort, at a specificity of 98.5%. Combining A-PLUS with aneuploidy and eight common protein biomarkers detected 51% of the cancers at 98.9% specificity. We found that part of the power of A-PLUS could be ascribed to a single feature-the global reduction of AluS subfamily elements in the circulating DNA of patients with solid cancer. We confirmed this reduction through the analysis of another independent dataset obtained with a different approach (whole-genome sequencing). The evaluation of Alu elements may therefore have the potential to enhance the performance of several methods designed for the earlier detection of cancer.
The invention relates to the drug preparation field, and aims to provide an externally-used burn drug having the advantages of simple preparation, use convenience, fast curative effect and no toxic side effects, and a use method thereof. The externally-used burn drug is composed of 6g of cooked Radix Scutellariae, 4g of Pu'er tea, 10g of Calligonum arborescens Litv. and 1200ml of water. The use method comprises the following steps: 1, crushing 6g of the cooked Radix Scutellariae and 4g of the Pu'er tea to form powder for later use; and 2, boiling 10g of the Calligonum arborescens Litv. in 1200ml of water, cooling the obtained decoction, cleaning burns with the obtained cooled decoction for thoroughly cleaning epidermal tissues on the burns, uniformly scattering the powder on the burns, momentarily dipping the tea decoction to prevent drug powder air-drying, and timely supplementing the tea decoction to the drug powder until the wound purulent matter flow caused by the drug effects of the drug powder is stopped. The practices of the above technical scheme show that the externally-used burn drug has the characteristics of easily available raw materials, use convenience, fast anti-inflammation and swelling elimination, good permeability, short treatment period, no scars, and no toxic side effects when the drug is used for treating the burns.
The invention discloses attapulgite/green tea fluoridated toothpaste and a production method thereof. The technical proposal is that: the production method comprises the following steps: steaming for enzyme deactivation, preparing ingredients, low-speed stirring, pulverization and pulping, milling, high-speed stirring, vacuum degassing and packaging. Through the steps, finished products of attapulgite/green tea fluoridated toothpaste are obtained. The attapulgite/green tea fluoridated toothpaste contains pasty attapulgite clay, fresh green tea, sodium monofluorophosphate, sodium dodecylsulfate, potassium sorbate, borneol and deionized water. The attapulgite/green tea fluoridated toothpaste has soft and fine texture and oral cleaning and refreshing functions. The attapulgite/green tea fluoridated toothpaste contains fluorine ions that are in free form and easily absorbed by teeth without damage to teeth, and can enhance and regenerate enamel on tooth surface, thereby providing functions of preventing dental caries and eliminating odors in oral cavity. The inventive method is suitable for the production of attapulgite/green tea fluoridated toothpaste, herbal fluoridated toothpaste and other medicinal fluoridated toothpaste.
PROBLEM TO BE SOLVED: To obtain a cosmetic containing complex silicone powder and improved in extensibility and inunction feeling. SOLUTION: This cosmetic contains a complex silicone powder obtained by applying a polyorganosylcesqueoxane resin of the formula, R<2> SiO3/2 (R<2> is an alkyl, an aryl, an alkenyl, an aralkyl, a monovalent halogenated hydrocarbon, etc.) to silicone rubber globular fine particles of the formula, (R<1> 2 SiO)a [R<1> is an alkyl, an aryl, an alkenyl, an aralkyl, a monovalent halogenated hydrocarbon, etc.; (a) is 5-500]. A method for applying the resin is as follows. An alkaline substance or an alkaline aqueous solution and an organotrialkoxysilane are added to a water dispersion of silicone rubber globular fine particles having 0.1-100μm average particle diameter. Thereby, hydrolysis and condensation reaction of the organotrialkoxysilane is carried out. The polyorganosilsesquioxane resin in an amount of 1-500 pts.wt. is applied to 100 pts.wt. silicone rubber globular fine particles.
For sedation during surgery, patients will receive i.v. propofol in dose 25-27 mcg/kg/min.
The invention provides an administration combination and a preparation method and a use method thereof. The administration combination comprises treatment components carrying effective doses, absorbefacient, medical auxiliary materials, and solid preparation of a bioadhesive layer containing bioadhesive polymer, and further comprises a selectable impervious or semi-permeable coating layer which ensures that the treatment components and the absorbefacient have unidirectional release capability. A unidirectional release channel with unidirectional release capability is formed through manual or laser ablation technology, and the releasing rates of the treatment components and the absorbefacient in the solid preparation are nearly the same. The invention simultaneously provides the preparation and the use methods of the administration combination. Low-dose solid preparation prepared through a non-solvent granulation process can maintain the uniformity and the stability of the treatment components. The administration combination can promote the absorption of drug difficult to be absorbed, improves the bioavailability, adjusts the pharmacodynamic feature and improves the absorption efficiency of drug, has a low price, and is relatively easy to produce.
A 55-year-old man presented to the emergency department with worsening shortness of breath 1 month after a gastrointestinal bleed. He had congestive heart failure, and an electrocardiogram suggested ischemic heart disease involvement. Echocardiography revealed a ventricular septal defect complicated by a left ventricular aneurysm in the inferior-posterior wall. Conservative treatment was started, but hemodynamic collapse occurred on the third day of admission and coronary angiography revealed a revascularizing lesion in the right fourth posterior descending coronary artery. Subsequently, his hemodynamic status continued to deteriorate, even with an Impella CP® heart pump, so ventricular septal defect patch closure and left ventricular aneurysm suture were performed. His condition improved and he was discharged on day 23 of admission and was not readmitted within 6 months after the procedure. Hemodynamic management of ventricular septal defects requires devices that reduce afterload, and clinicians should be aware of the risk of myocardial infarction after gastrointestinal bleeding.
Ischaemic spinal cord injury remains a significant challenge in thoracoabdominal aortic repairs. Modern techniques have reduced spinal cord injury rates yet managing patients during and after thoracoabdominal aortic repairs remains complex. This article outlines our comprehensive approach to the prevention of spinal cord injuries in open thoracoabdominal aortic repair operations, focusing on the placement of cerebrospinal fluid drain and intraoperative strategies to enhance spinal cord protection. Preoperative planning involves thorough patient assessment, prehabilitation and nutritional support, detailed imaging review, thorough operative planning and patient blood management. Intraoperative measures include the use of neuromonitoring techniques like near-infrared spectroscopy and motor evoked potentials, as well as cerebrospinal fluid drainage together with blood pressure management to optimize spinal cord perfusion. Postoperative management focuses on maintaining haemodynamic stability with high mean arterial pressure, along with close monitoring and management of the cerebrospinal fluid drain to improve spinal cord perfusion. Additionally, thromboelastography-guided strategies are crucial for optimizing coagulation and addressing postoperative bleeding complications. The goal of this multifaceted approach is to minimize the risk of spinal cord injury, thereby improving patient outcomes and reducing the incidence of postoperative paraplegia. Our video tutorial shows some of our preoperative and intraoperative techniques for spinal cord protection in thoracoabdominal aortic repairs.
All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment \>2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.